On February 28, 2022 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported that the Company will participate in the "Novel Oncology Targets" panel at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 12:50 p.m. ET (Press release, Fusion Pharmaceuticals, FEB 28, 2022, View Source [SID1234609182]). Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for approximately 30 days following the panel discussion.